GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kane Biotech Inc (TSXV:KNE) » Definitions » EV-to-EBIT

Kane Biotech (TSXV:KNE) EV-to-EBIT : -4.70 (As of Sep. 26, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Kane Biotech EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Kane Biotech's Enterprise Value is C$19.27 Mil. Kane Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was C$-4.10 Mil. Therefore, Kane Biotech's EV-to-EBIT for today is -4.70.

The historical rank and industry rank for Kane Biotech's EV-to-EBIT or its related term are showing as below:

TSXV:KNE' s EV-to-EBIT Range Over the Past 10 Years
Min: -33.73   Med: -3.92   Max: -0.9
Current: -4.7

During the past 13 years, the highest EV-to-EBIT of Kane Biotech was -0.90. The lowest was -33.73. And the median was -3.92.

TSXV:KNE's EV-to-EBIT is ranked worse than
100% of 440 companies
in the Biotechnology industry
Industry Median: 8.91 vs TSXV:KNE: -4.70

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Kane Biotech's Enterprise Value for the quarter that ended in Jun. 2024 was C$21.25 Mil. Kane Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was C$-4.10 Mil. Kane Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -19.28%.


Kane Biotech EV-to-EBIT Historical Data

The historical data trend for Kane Biotech's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kane Biotech EV-to-EBIT Chart

Kane Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.55 -5.11 -5.34 -6.04 -6.33

Kane Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.76 -6.43 -6.33 -7.34 -5.19

Competitive Comparison of Kane Biotech's EV-to-EBIT

For the Biotechnology subindustry, Kane Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kane Biotech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kane Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kane Biotech's EV-to-EBIT falls into.



Kane Biotech EV-to-EBIT Calculation

Kane Biotech's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=19.266/-4.097
=-4.70

Kane Biotech's current Enterprise Value is C$19.27 Mil.
Kane Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kane Biotech  (TSXV:KNE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Kane Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=-4.097/21.2528
=-19.28 %

Kane Biotech's Enterprise Value for the quarter that ended in Jun. 2024 was C$21.25 Mil.
Kane Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kane Biotech EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Kane Biotech's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Kane Biotech Business Description

Traded in Other Exchanges
Address
290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The Company has a separate operating segment for its Stem Animal Health subsidiary, which operates the animal health business. StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, DermaKB and DermaKB Biofilm are trademarks of the company. The firm is also engaged in the animal health business through its Stem Animal Health subsidiary.
Executives
Philip Renaud Director

Kane Biotech Headlines

No Headlines